Meetings start at 8:30 a.m. and end by 10:00 a.m. Gather early for coffee and conversation.
Our speaker for Saturday, November 18, 2017, will be Lewis H. Bender President and CEO of Intensity Therapeutics.
Intensity Therapeutics is a clinical-stage biotechnology company whose mission is to greatly extend the lives of patients with cancer. The company’s proprietary DfuseRxSM platform technology creates novel immune-based therapeutic products that can directly kill tumors and stimulate a strong adaptive immune response in certain cancer types. This approach is a new and emerging field of cancer treatment known as in situ vaccination.
Every once and a while we ask you to check a date on your calendar. Why? Because there is usually a compelling reason and this Saturday, November 18 is one such occasion.
Our speaker is Lewis H Bender. Lewis is the founder, president, and CEO of Intensity Therapeutics, a clinical-stage biotechnology company pioneering a new and different immune-based drug therapy approach to treat cancer. In less than four and a half years Mr. Bender has led the company from an idea (worked out in his basement) to an International clinical trial at leading U.S. and Canadian academic hospitals testing the novel cancer treatment concept.
Both the U.S. FDA and Health Canada regulatory agencies reviewed the company’s product dossier to permit the start of the human studies in cancer patients.
The Company has raised million dollars since inception and the U.S. Patent and Trademark Office, as well as a number of foreign countries, granted patents to the Company. The company was awarded a Collaborative Research and Development Agreement by the National Cancer Institute in 2014.
Mr. Bender has over 25 years of biotech and pharmaceutical experience having led teams taking products from discovery to Phase III for compounds in several different therapeutic fields. In addition, over his career, Mr. Bender has been successful in raising (or helping to raise) over $300 million in capital with institutional investors
Mr. Bender has a Bachelors of Science and Masters of Science in Chemical Engineering from the Massachusetts Institute of Technology (MIT), a Masters of Business Administration from the University of Pennsylvania’s (UPenn) Wharton School and a Master of Arts in International Studies.
Raised in the United States, Mr. Bender spent several years living in Switzerland and speaks fluent French, German and the Swiss-German dialect. He is the author of several articles on various aspects of the pharmaceutical industry. Lewis H Bender is a Weston resident.
Sound interesting? Let me know if I can save you a seat.
Tom Glass, Chair